[RNA干扰疗法在肿瘤学中的机遇与挑战]
[Opportunities and Challenges of RNA Interference Therapeutics in Oncology].
作者信息
Chen Rui, Xu Yan
机构信息
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):482-486. doi: 10.3779/j.issn.1009-3419.2022.102.20.
As the discovery of RNA interference (RNAi) and the gradual conquering of a series of technical issues, a few of RNAi therapeutics have been approved in the non-tumor field abroad. With the advantages of high specificity, long duration of efficacy, and high success rate of development, RNAi therapeutics have become the emerging field globally. There are no RNAi therapeutics approved in oncology so far, and people are hoping a breakthrough in the field. In the present article, the characteristics and potential anti-tumor mechanism of RNAi therapeutics, difficulties in delivery system and progress in oncology are described, and the potential reasons why their success in non-tumor field is difficult to be simply replicated in tumor field are analyzed, providing reference for research and clinical transformation of RNAi therapeutics in oncology. .
随着RNA干扰（RNAi）的发现以及一系列技术问题的逐步攻克，国外已有数种RNAi疗法在非肿瘤领域获批。RNAi疗法具有特异性高、疗效持续时间长、研发成功率高等优点，已成为全球新兴领域。目前尚无RNAi疗法在肿瘤学领域获批，人们期待该领域取得突破。本文阐述了RNAi疗法的特点、潜在抗肿瘤机制、递送系统方面的困难以及在肿瘤学领域的进展，并分析了其在非肿瘤领域的成功难以简单复制到肿瘤领域的潜在原因，为RNAi疗法在肿瘤学中的研究及临床转化提供参考。
Zotero 插件